EMA – First oral treatment for spinal muscular atrophy (SMA) recommended for approval
EMA has recommended granting a marketing authorisation in the European Union for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement. Evrysdi is indicated for the treatment of 5q SMA…
